Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs

Health Affairs

Volumn 31, Issue 9, 2012, Pages 2051-2058

  Swaminathan, Shailender ^a   Mor, Vincent ^a,b   Mehrotra, Rajnish ^a,c,d   Trivedi, Amal ^e  

^a BROWN UNIVERSITY   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ARTICLE; DIALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; KIDNEY FAILURE; MEDICARE; PERSONNEL MANAGEMENT; REIMBURSEMENT;

COST CONTROL; HUMANS; KIDNEY FAILURE, CHRONIC; MEDICARE; REIMBURSEMENT MECHANISMS; REIMBURSEMENT, INCENTIVE; UNITED STATES;

EID: 84871902888     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0368     Document Type: Article

References (40)

1. Blagg CR. The early history of dialysis for chronic renal failure in the United States: a view from Seattle. Am J Kidney Dis. 2007; 49(3):482-96.
2. Knauf F, Aronson PS. ESRD as a window into America's cost crisis in health care. J Am Soc Nephrol. 2009; 20:2093-7.
3. Cooper AL, Trivedi AN. Fitness memberships and favorable selection in Medicare Advantage plans. N Engl J Med. 2012;366:150-7.
4. Whoriskey P. Anemia drugs made billions, but at what cost? Washington Post. 2012 Jul 19.
5. US Renal Data System. 2006 annual data report [Internet]. Bethesda (MD): National Institutes of Health; 2006 [cited 2012 Aug 14]. Available for download from: http://www.usrds.org/atlas06.aspx
6. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339: 584-90.
7. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-98.
8. Drüeke TB, Locatelli F, Clyne N, Eckardt K, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin levels in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20): 2071-84.
9. Medicare Payment Advisory Commission. Report to the Congress: Medicare payment policy [Internet]. Washington (DC): MedPAC; 2011 Mar [cited 2012 Jul 24]. Available from: http://medpac.gov/ documents/Mar11_EntireReport.pdf
10. Committee on Chronic Kidney Disease. Gottschalk report. Washington (DC): Bureau of the Budget; 1967.
11. Rettig RA, Marks EL. Implementing the end-stage renal disease program of Medicare: Health Care Financing Administration. Washington (DC): Government Printing Office; 1981. (Pub. No. 03085).
12. Rettig RA, Levinsky NG, editors. Kidney failure and the federal government. Washington (DC): National Academies Press; 1991.
13. Eggers PW. Trends in Medicare reimbursement for end-stage renal disease: 1974-1979. Health Care Financ Rev. 1984;6(1): 31-8.
14. US Renal Data System. 2002 annual data report [Internet]. Bethesda (MD): National Institutes of Health; 2002 [cited 2012 Aug 14]. Available for download from: http://www.usrds.org/atlas02.aspx
15. Dobson A, Langenbrunner JC, Pelovitz SA, Willis JB. The future of Medicare policy reform: priorities for research and demonstrations. Health Care Financ Rev. 1986;(Spec No):1-7.
16. Himmelfarb J, Berns A, Szczech L, Wesson D. Cost, quality, and value: the changing political economy of dialysis care. J Am Soc Nephrol. 2007;18(7): 2021-7.
17. US Congress Office of Technology Assessment. Payment for physician services: strategies for Medicare [Internet]. Washington (DC): Government Printing Office; 1986 Feb [cited 2012 Aug 2]. (Pub. No. OTAH-294). Available from: http://www.fas.org/ota/reports/8618.pdf
18. Pauly MV, Langwell KM. Physician payment reform: who shall be paid? Med Care Rev. 1986;43(1):101-32.
19. Office of Inspector General. Effect of interim rate for drug Epogen on Medicare expenditures and dialysis facility operation. Washington (DC): Department of Health and Human Services; 1990. (Pub. No. A-01-90-00512).
20. Varian H. Intermediate microeconomics: a modern approach. 8th ed. New York (NY): W.W. Norton and Company; 2009.
21. Kleinke JD. Re-naming and regaming: Medicare's doomed attempt to reform reimbursement for injectable drugs. Health Aff (Millwood). 2004;23:w4-561-71. DOI: 10.1377/ hlthaff.w4.561.
22. Brookhart AM, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010;303(9): 857-64.
23. Office of Inspector General. Medicare reimbursement for existing endstage renal disease drugs. Washington (DC): Department of Health and Human Services; 2004.
24. Office of Inspector General. Medicare reimbursement for existing endstage renal disease drugs. Washington (DC): Department of Health and Human Services; 2006.
25. CMS.gov. Renal Management Information System (REMIS) [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [last modified 2012 Feb 27; cited 2012 Aug 14]. Available from: http://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/ IdentifiableDataFiles/Renal ManagementInformationSystem .html
26. CMS.gov. Renal facility [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [last modified 2012 Aug 13; cited 2012 Aug 14]. Available from: http://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/CostReports/RenalFacility.html
27. Medicare Payment Advisory Commission. Report to the Congress: variation and innovation in Medicare [Internet]. Washington (DC): MedPAC; 2003 Jun [cited 2012 Jul 24]. Available from: http:// www.medpac.gov/documents/ June03_Entire_Report.pdf
28. Milgate K, Cheng SB. Pay-forperformance: the MedPAC perspective. Health Aff (Millwood). 2006; 25(2):413-9.
29. Fairbrother G, Hanson KL, Friedman S, Butts GC. The impact of physician bonuses, enhanced fees, and feedback on childhood immunization coverage rates. Am J Public Health. 1999;89(2):171-5.
30. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington (DC): National Academies Press; 2001.
31. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26): 2635-45.
32. Cromwell J, Dayhoff DA, Thoumaian AH. Cost savings and physician responses to global bundled payments for Medicare heart bypass surgery. Health Care Financ Rev. 1997;19(1): 41-57.
33. Winkelmayor WC, Chertow GM. The 2011 ESRD prospective payment system: an uncontrolled experiment. Am J Kidney Dis. 2011;57(4):542-6.
34. Newhouse J. Reimbursing health plans and health providers: efficiency in production and selection. J Econ Lit. 1996;34(3):1236-63.
35. Centers for Medicare and Medicaid Services. Medicare program; endstage renal disease prospective payment system; final rule and proposed rule. Fed Regist. 2010; 75(155):49030-214.
36. Centers for Medicare and Medicaid Services. Medicare program; endstage renal disease quality incentive program; final rule. Fed Regist. 2011;76(3):628-46.
37. Iglehart JK. Bundled payment for ESRD-including ESAs in Medicare's dialysis package. N Engl J Med. 2011;364(7):593-5.
38. Nissenson AR, Rettig RA. Medicare's end-stage renal disease program: current status and future prospects. Health Aff (Millwood). 1999;18(1): 161-79.
39. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17(4):1181-91.
40. Molnar MZ, Mehrotra R, Duong U, Kovesdy CP, Kalantar-Zadeh K. Association of hemoglobin and survival in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2011;6(8):1973-81.